These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 23090595

  • 1. Current and future challenges in the development of antimicrobial agents.
    Rennie RP.
    Handb Exp Pharmacol; 2012; (211):45-65. PubMed ID: 23090595
    [Abstract] [Full Text] [Related]

  • 2. [Gram-positive bacterial infections resistant to antibiotic treatment].
    Utili R.
    Ann Ital Med Int; 2001; 16(4):205-19. PubMed ID: 11799629
    [Abstract] [Full Text] [Related]

  • 3. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H, Hayakawa I, Akimoto T.
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Trends in antimicrobial resistance among today's bacterial pathogens.
    Thornsberry C.
    Pharmacotherapy; 1995 Jul; 15(1 Pt 2):3S-8S. PubMed ID: 7753690
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Optimizing therapy for vancomycin-resistant enterococci (VRE).
    Linden PK.
    Semin Respir Crit Care Med; 2007 Dec; 28(6):632-45. PubMed ID: 18095227
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tigecycline.
    Pankey GA.
    J Antimicrob Chemother; 2005 Sep; 56(3):470-80. PubMed ID: 16040625
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial resistance in Europe and its potential impact on empirical therapy.
    Rossolini GM, Mantengoli E.
    Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():2-8. PubMed ID: 19040461
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial resistance in gram-positive bacteria.
    Rice LB.
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S11-9; discussion S64-73. PubMed ID: 16813977
    [Abstract] [Full Text] [Related]

  • 14. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA, Jones RN, Leeds JA, Denys G, Sader HS, Fritsche TR.
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antimicrobial resistance in gram-positive bacteria.
    Rice LB.
    Am J Med; 2006 Jun; 119(6 Suppl 1):S11-9; discussion S62-70. PubMed ID: 16735146
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of ertapenem: review of recent studies.
    Wexler HM.
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH, Wang JT, Chen YC, Chang SC, Luh KT.
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.